Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells.
Androgens via their receptor (AR) may play a role in prostate cancer etiology. This study focuses on the inhibitory effects of resveratrol on androgen action in the LNCaP prostate cancer cell line. We found that resveratrol represses different classes of androgen up-regulated genes at the protein or mRNA level including prostate-specific antigen, human glandular kallikrein-2, AR-specific coactivator ARA70, and the cyclin-dependent kinase inhibitor p21. This inhibition is likely attributable to a reduction in AR contents at the transcription level, inhibiting androgen-stimulated cell growth and gene expression. This study suggests that resveratrol may be a useful chemopreventive/chemotherapeutic agent for prostate cancer.